0001231919-20-000013.txt : 20200311 0001231919-20-000013.hdr.sgml : 20200311 20200310222348 ACCESSION NUMBER: 0001231919-20-000013 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20200311 DATE AS OF CHANGE: 20200310 EFFECTIVENESS DATE: 20200311 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Outlook Therapeutics, Inc. CENTRAL INDEX KEY: 0001649989 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 383982704 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-362487 FILM NUMBER: 20703810 BUSINESS ADDRESS: STREET 1: 7 CLARKE DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 BUSINESS PHONE: 6096193990 MAIL ADDRESS: STREET 1: 7 CLARKE DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 FORMER COMPANY: FORMER CONFORMED NAME: Oncobiologics, Inc. DATE OF NAME CHANGE: 20150804 D 1 primary_doc.xml X0708 D LIVE 0001649989 Outlook Therapeutics, Inc. 7 CLARKE DRIVE CRANBURY NJ NEW JERSEY 08512 6096193990 DELAWARE Oncobiologics, Inc. Corporation true Randy Thurman c/o Outlook Therapeutics, Inc. 7 Clarke Drive CRANBURY NJ NEW JERSEY 08512 Director Yezan Haddadin c/o Outlook Therapeutics, Inc. 7 Clarke Drive CRANBURY NJ NEW JERSEY 08512 Director Kurt J. Hilzinger c/o Outlook Therapeutics, Inc. 7 Clarke Drive CRANBURY NJ NEW JERSEY 08512 Director Lawrence A. Kenyon c/o Outlook Therapeutics, Inc. 7 Clarke Drive CRANBURY NJ NEW JERSEY 08512 Executive Officer Director Faisal G. Sukhtian c/o Outlook Therapeutics, Inc. 7 Clarke Drive CRANBURY NJ NEW JERSEY 08512 Director Terry Dagnon c/o Outlook Therapeutics, Inc. 7 Clarke Drive Cranbury NJ NEW JERSEY 08512 Executive Officer Jeff Evanson c/o Outlook Therapeutics, Inc. 7 Clarke Drive Cranbury NJ NEW JERSEY 08512 Executive Officer Other Decline to Disclose 06b false 2020-02-24 false true true true false 0 H.C. Wainwright & Co., LLC 375 None None 430 Park Avenue NewYork NY NEW YORK 10022 IL ILLINOIS NJ NEW JERSEY NY NEW YORK false 7971155 7971155 0 Includes amounts receivable upon the exercise of warrants; such warrants have not yet been exercised false 7 540400 0 In addition, the placement agent was reimbursed $135,000 for expenses relating to the offering and received $77,200 for management fees. 0 false Outlook Therapeutics, Inc. /s/ Lawrence Kenyon Lawrence Kenyon Chief Executive Officer 2020-03-10